Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry (PROMET II)
Status
Conditions
Treatments
Details and patient eligibility
About
The recent data suggest that cancer cells at the origin of prostate cancer metastases can be detected in an early stage. Available techniques allow phenotypic analysis of cancer cells in circulating blood (cellsearch) or in marrow hematopoietic (flow cytometry). Pilot study on 180 patients infected by prostate cancer at all stage of disease, show that c-met marker , integrin alpha 2 and 6 expressed in marrow and quantified by flow cytometry were predictor of metastatic progress. In this new study the investigators will analyze antibody panel by cellsearch and flow cytometry on marrow sample of castration-Resistant prostate cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Histologically confirmed adenocarcinoma or prostate
- Ongoing effective androgen deprivation therapy (testosterone ≤ 50 ng/mL)
- Castration-Resistant prostate cancer patient : defined as a minimum of 3 rising PSA values assessed and/or radiological progress confirmed by RECIST and PCWG2
- Patient who signed informed consent
Exclusion criteria
- Severe disorders of coagulation
- Major skin lesion on iliac crests
- Allergies in local anesthetics
- Psychological instability or psychiatric histories
- Uncertain follow-up and distant residence
- History of another invasive cancer and hematologic disease
- Patient deprived of their freedom by court or administrative order
- Revocation of consent
Trial design
Primary purpose
Allocation
Interventional model
Masking
17 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal